Results 1 to 10 of about 14,264 (186)

Cloning and Extracellular Expression of Glargine in Pichia pastoris [PDF]

Hayati Journal of Biosciences, 2023
Patients with diabetes mellitus increase significantly every year. The increasing number of people with diabetes mellitus results in increased insulin requirements.
Dudi Hardianto, Efrida Martius, Tina Rostinawati, Anna Safarrida, Juwartina Ida Royani, Fahroziah Assyifa, Dihan Laziba   +6 more
doaj   +2 more sources

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. [PDF]

PLoS ONE, 2012
AimThe role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.MethodsAll observational studies and randomized ...
Xulei Tang, Lin Yang, Zhiyu He, Jingfang Liu   +3 more
doaj   +2 more sources

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect [PDF]

Сахарный диабет, 2014
Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection.
Vadim Valer'evich Klimontov, Natalya Evgen'evna Myakina   +1 more
doaj   +2 more sources

Efficient Extracellular Production of Insulin Glargine in Trichoderma reesei by an Integrative Secretion-Based Strategy. [PDF]

Microb Biotechnol
Insulin glargine, a long‐acting insulin analog, is essential for diabetes treatment. However, its industrial production remains challenging due to limitations in conventional expression systems.
Yan A, Li X, Zhang D, Li L, Liu J, Si X, Li K, Luan Q, Liu H, Zhong Y.   +9 more
europepmc   +2 more sources

Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety

Медицинский совет, 2021
In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose ...
E. V. Biryukova, M. V. Shinkin, O. M. Mikheeva   +2 more
doaj   +1 more source

Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. [PDF]

PLoS ONE, 2014
Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with diabetes for up to 6 years ...
Soo Lim, Katherine G Stember, Wei He, Porneala C Bianca, Carine Yelibi, Alison Marquis, Til Stürmer, John B Buse, James B Meigs   +8 more
doaj   +1 more source

Insulin choice in feline diabetes mellitus

Veterinary Evidence, 2021
PICO question In cats with diabetes mellitus, do protamine zinc insulin (PZI) and glargine show a similar effect in reducing clinical signs and hypoglycaemia episodes?
Yaiza Gomez Mejias
doaj   +1 more source

Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials

Сахарный диабет, 2023
Initiation of insulin therapy with basal insulin analogues has become the standard of care for type 2 diabetes mellitus (T2DM). Timely administration of insulin allows not only to slow down the progression of type 2 diabetes, but also to reduce the ...
S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. O. Lutova, E. A. Popova   +4 more
doaj   +1 more source

Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO

Сахарный диабет, 2022
Background: The effectiveness and safety of a fixed combination of insulin glargine 100 ME/ml and lixisenatide for treatment of patients with type 2 diabetes (T2DM) has been demonstrated in randomized clinical trials, but there are still not enough data ...
M. B. Antsiferov, N. A. Demidov, M. A. Balberova, T. I. Safronova, O. A. Mishra, S. G. Magomedova   +5 more
doaj   +1 more source

Insulin glargine overdose

Journal of Pharmacology and Pharmacotherapeutics, 2012
Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual.
Doğan, Fatma Sarı, Onur, Özge Ecmel, Altınok, Arzu Denizbaşı, Güneysel, Özlem   +3 more
openaire   +4 more sources